Kidney failure and its treatment may impact cancer risk
For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published in a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN), suggest the need for persistent cancer screening and prevention in these patients.
People with kidney failure are at increased risk of developing different types of cancer, which might be due to a variety of factors related to their disease and the treatments they receive. Often these patients undergo intervals of dialysis followed by transplantation, and then they return to dialysis if the transplant fails. Understanding how these different exposures correspond to cancer risk can help inform cancer prevention and screening decisions for patients and can provide insights into the underlying causes of cancer.
To investigate, Elizabeth Yanik, PhD, ScM (National Cancer Institute) and her colleagues evaluated information on 202,195 kidney transplant candidates and recipients by linking the Scientific Registry of Transplant Recipients to various US population-based cancer registries. For a number of cancers, the team observed clear patterns of risk that corresponded to different treatment intervals. For example, risk of kidney and thyroid cancers was high across all intervals, but the risk was particularly heightened when individuals were on dialysis. Conversely, risk of non-Hodgkin lymphoma, melanoma, lung cancer, and certain skin cancers was highest following kidney transplantation and—for those who experienced it— prior to transplant failure. This may have been due to the effects of immunosuppressant medications that are needed while living with a functioning kidney transplant.
"Our study indicates that the needs of individuals with end-stage renal disease, in terms of cancer prevention and cancer screening, will likely differ over time," said Dr. Yanik. "Vigilance for kidney cancer and thyroid cancer may be of particular importance while these individuals are on dialysis. Extra consideration for screening for melanoma or lung cancer may be called for while taking immunosuppressant medications following a kidney transplant."
In an accompanying editorial, Wai Lim, PhD (University of Western Australia) and Steven Chadban, PhD (University of Sydney) noted that "the epidemiologic insights provided by Yanik et al. may have important implications for the pathogenesis and mechanism of cancer development in patients."
The editorial, entitled "Cancer in ESRD: Clear on the Epidemiology, Hazy on the Mechanisms," will appear online at jasn.asnjournals.org/ on November 12, 2015.